Merck to slash $3B in costs as patent cliff for hallmark cancer med nears

Crain's New York Business

Jul 30, 2025

Merck is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world. The drugmaker will…